Preview

Онкогематология

Расширенный поиск

Целесообразность проведения KIR-типирования при подборе донора для аллогенной трансплантации гемопоэтических стволовых клеток: обзор литературы

https://doi.org/10.17650/1818-8346-2019-13-4-67-74

Полный текст:

Аннотация

Естественные киллерные (natural killer, NK) клетки являются 1-й популяцией лимфоцитов, которая восстанавливается после аллогенной трансплантации гемопоэтических стволовых клеток (ТГСК). После того как в 2002 г. L. Rugerri и соавт. показали роль NK-аллореактивности при гаплоидентичной ТГСК, появилось множество противоречивых исследований о NK-аллореактивности при гаплоидентичной и совместимой неродственной ТГСК. Современные представления говорят о влиянии на NK-аллореактивность трансплантационного протокола ‒ вида режима кондиционирования, процессинга трансплантата, а также посттрансплантационной профилактики реакции «трансплантат против хозяина».

Об авторе

В. В. Захарова
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия

Виктория Витальевна Захарова 

117997 Москва, ул. Саморы Машела, 1



Список литературы

1. Cooley S., Trachtenberg E., Bergemann T.L. et al. Donor with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009;113(3):726–32. DOI: 10.1182/blood-2008-07-171926. PMID: 18945962.

2. Spierings E., Kim Y., Hendriks M. et al. Multicenter analyses demonstrate significant clinical effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19(8):1244–53. DOI: 10.1016/j.bbmt.2013.06.001. PMID: 23756210.

3. Rugerri L., Capanni M., Casucci M. et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94(1):333–9. PMID: 10381530.

4. The HLA complex in Biology and Medicine: A Resource Book. Eds.: N.K. Mehra, G. Kaur, J. McCluskey et al. New Delhi: Jaypee Brothers Medical Publishers LTD, 2010.

5. Ciccone E., Viale O., Pende D. et al. Specific lysis of allogeneic cells after activation of CD3-lymphocytes in mixed lymphocyte culture. J Exp Med 1988;168(6):2403–8. PMID: 2974067.

6. Moretta A., Bottino C., Pende D. et al. Identification of four subsets of human CD3 – CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: Correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990;172(6):1589–98. PMID: 2147946.

7. Ciccone E., Pende D., Moretta A. et al. Evidence of natural killer (NK) cell repertoire for (Allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 1992;175(3):709–18. PMID: 1371301.

8. Ciccone E., Pende D., Viale O. et al. Involvement of HLA Class 1 alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones dysplaing a defined specificity. J Exp Med 1992;176(4):963–71. PMID: 1328466.

9. Colonna M., Brooks E.G., Falco M. et al. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 1993;260(5111):1121–4. PMID: 8493555.

10. Cella M., Longo A., Ferrara G.B. et al. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994;180(4):1235–42. PMID: 7931060.

11. Foley B.A., De Santis D.D., Van Beelen E. et al. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 2008;112(2):435–43. DOI: 10.1182/blood-2008-01-132902. PMID: 18385451.

12. Ljunggren H.G., Karre K. In search of the “missing self”: MHC molecules and NK cell recognition. Immunol Today 1990;11(7):237–44. PMID: 2201309.

13. Oevermann L., Michaelis S.U., Mezger M. et al. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood 2014;124(17):2744–7. DOI: 10.1182/blood-2014-03-565069. PMID: 25115891.

14. Uhrberg M., Valiante N.M., Shum B.P. et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997;7(6):753–63. PMID: 9430221.

15. Witt C.S., Dewing C.B., Sayer D.C. et al. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation 1999;68(11):1784–9. PMID: 10609957.

16. Savani B.N., Mielke S., Adams S. et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007;21(10):2145–52. DOI: 10.1038/sj.leu.2404892. PMID: 17673900.

17. Stewart C.A., Laugier-Anfossi F., Vely F. et al. Recognition of peptide-MHC class 1 complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005;102(37):13224–9. DOI: 10.1073/pnas.0503594102. PMID: 16141329.

18. Chewning J.H., Gudme C.N., Hsu K.C. et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 2007;179(2):854–68. PMID: 17617576.

19. Rugerri L., Capanni M., Urbani E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295(5562):2097–100. DOI: 10.1126/science.1068440. PMID: 11896281.

20. Ghayur T., Seemayer T.A., Kongshavn P.A. et al. Graft-versus-host reactions in the beige mouse: an investigation of the role of host and donor natural killer cells in the pathogenesis of graft-versushost disease. Transplantation 1987;44(2):261–7. PMID: 3307050.

21. Cooley S., McCullar V., Wangen R. et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005;106(13): 4370–6. DOI: 10.1182/blood-2005-04-1644. PMID: 16131567.

22. Yabe T., Matsuo K., Hirayasu K. et al. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-CKIR ligand-mismatched T cellreplete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 2008;14(1):75–87. DOI: 10.1016/j.bbmt.2007.09.012. PMID: 18158964.

23. Rhoades J.L., Cibull M.L., Thompson J.S. et al. Role of natural killer cells in the pathogenesis of human acute graftversus-host disease. Transplantation 1993;56(1):113–20. PMID: 8333033.

24. Ferrara J.L., Guillen F.J., Dijken P.J. et al. Evidence that large granular lymphocytes of donor origin mediate acute graft-versushost disease. Transplantation 1989;47(1):50–4. PMID: 2643231.

25. Shilling H.G., McQueen K.L., Cheng N.W. et al. Reconstitution of NK cell receptor repertoire following HLAmatched hematopoietic stem cell transplantation. Blood 2003;101(9):3730–40. DOI: 10.1182/blood-2002-08-2568. PMID: 12511415.

26. Pende D., Marcenaro S., Falco M. et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009;113(13):3119–29. DOI: 10.1182/blood-2008-06-164103. PMID: 18945967.

27. Vago L., Forno B., Sormani M.P. et al. Temporal, quantitative, and functional characteristics of single KIR positive alloreactive natural killer cell recovery account for impaired graft-versusleukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008;112(8):3488–99. DOI: 10.1182/blood-2007-07-103325. PMID: 18645039.

28. Rugerri L., Mancusi A., Capanni M. et al. Donor natural killer cell allorecognition of “missing self” in haploidentical hematpoietic stem cell transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110(1):433–40. DOI: 10.1182/blood-2006-07-038687. PMID: 17371948.

29. Locatelli F., Pende D., Maccario R. et al. Haploidentical hematopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol 2009;133(2):171–8. DOI: 10.1016/j.clim.2009.04.009. PMID: 19481979.

30. Triplett B., Handgretinger R., Pui C.H., Leung W. KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood 2006;107(3):1238–9. DOI: 10.1182/blood-2005-07-2809. PMID: 16434496.

31. Leung W., Iyengar R., Turner V. et al. Determinants of antileukemia effect of allogenic NK cells. J Immunol 2004;172(1):644–50. PMID: 14688377.

32. Bishara A., Santis D.D., Witt C.C. et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004;63(3):204–11. DOI: 10.1111/j.0001-2815.2004.00182.x. PMID: 14989709.

33. Huang X.J., Zhao X.Y., Liu D.H. et al. Deleterious effect of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemi 2007;21(4):848–51. DOI: 10.1038/sj.leu.2404566. PMID: 17268518.

34. Zhao X.Y., Huang K.Y., Liu K.Y. et al. Prognosis after unmanipulated HLAhaploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Eur J Haematol 2007;78(4):338–46. DOI: 10.1111/j.1600-0609.2007.00822.x. PMID: 17378893.

35. Giebel S., Dziaczkowska J., Wojnar J. et al. The impact of immunosuppressive therapy on an early quantitative NK cell reconstitution after allogeneic hematopoietic stem cell transplantation. Ann Transplant 2005;10(2):29–33. PMID: 16218030.

36. Muller C., Schernthaner G., Kovarik J. et al. Natural killer cell activity and antibody-dependent cellular cytotoxicity in patients under various immunosuppressive regimens. Clin Immunol Immunopathol 1987;44(1):12–9. PMID: 3297437.

37. Wang H., Grzywacz B., Sukovich D. et al. The unexpected effect of cyclosporine A on CD56+. Blood 2007;110(5):1530–9. DOI: 10.1182/blood-2006-10-048173. PMID: 17495133.


Для цитирования:


Захарова В.В. Целесообразность проведения KIR-типирования при подборе донора для аллогенной трансплантации гемопоэтических стволовых клеток: обзор литературы. Онкогематология. 2018;13(4):67-74. https://doi.org/10.17650/1818-8346-2019-13-4-67-74

For citation:


Zakharova V.V. Role of KIR typing in donor selection prior to allogeneic hematopoietic stem cell transplantation: literature review. Oncohematology. 2018;13(4):67-74. (In Russ.) https://doi.org/10.17650/1818-8346-2019-13-4-67-74

Просмотров: 31


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8346 (Print)
ISSN 2413-4023 (Online)